Trial Profile
A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Danusertib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Aug 2012 Primary endpoint 'Prostate-specific-antigen-response-rate' has not been met, according to results reported in BJU International.
- 29 Aug 2012 Results published in the BJU International.
- 04 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.